LncRNA GAS6-AS2 Promotes Non-small-cell Lung Cancer Cell Proliferation Via Regulating MiR-144-3p/ MAPK6 Axis

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2021 Jan 18

PMID 33459113

Citations 6

Authors

Guangjie Hou

Junfeng Yang

Jinxing Tang

Yi He

Affiliations

Soon will be listed here.

Abstract

The function of a new long non-coding RNA GAS6-AS2 in non-small cell lung cancer (NSCLC) is not fully understood. In this study, GAS6-AS2 was identified, and its roles as well as mechanisms in regulating proliferation of NSCLCs cells were investigated. qRT-PCR was used to analyze GAS6-AS2, miR-144-3p, and MAPK6 expression. Protein expression was detected by Western blotting. Cell Counting Kit-8 (CCK8) assay was used to examine the cell proliferation ability. The interaction between GAS6-AS2 and miR-144-3p was confirmed by dual-luciferase reporter assay and RNA pull down assay. A xenograft model was constructed to monitor the mice NSCLC tumor growth . GAS6-AS2 was up-regulated, while miR-144-3p was suppressed in NSCLC cells compared with normal lung cells. GAS6-AS2 suppression could inhibit the progression of NSCLC cells, and miR-144-3p could attenuate the effect. GAS6-AS2 could function as a competitive endogenous RNA (ceRNA) via direct sponging miR-144-3p-3p, which further regulating the expression of MAPK6. The knockdown of GAS6-AS2 could greatly suppress the tumor growth of NSCLC . GAS6-AS2 up-regulated MAPK6 by sponging miR-144-3p in NSCLC tissues and cells. Thus, GAS6-AS2 is an effective therapeutic target in NSCLC.

Citing Articles

ERK3 is involved in regulating cardiac fibroblast function.

Sahadevan P, Dingar D, Nawaito S, Nair R, Trepanier J, Sahmi F Physiol Rep. 2024; 12(11):e16108.

PMID: 38872461 PMC: 11176743. DOI: 10.14814/phy2.16108.

miR-144-3p represses hepatocellular carcinoma progression by affecting cell aerobic glycolysis via FOXK1.

Xing B, Shen C, Yang Q, Wang Z, Tan W Int J Exp Pathol. 2023; 104(3):117-127.

PMID: 36806218 PMC: 10182365. DOI: 10.1111/iep.12468.

MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.

Petkova V, Marinova D, Kyurkchiyan S, Stancheva G, Mekov E, Kachakova-Yordanova D Medicine (Baltimore). 2022; 101(33):e30027.

PMID: 35984198 PMC: 9388044. DOI: 10.1097/MD.0000000000030027.

Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis and .

Cui H, Ren G, Hu X, Xu B, Li Y, Niu Z Ren Fail. 2022; 44(1):1070-1082.

PMID: 35793478 PMC: 9272941. DOI: 10.1080/0886022X.2022.2092001.

The Role of RNA-Binding Protein HuR in Lung Cancer by RNA Sequencing Analysis.

Ye X, Fu Q, Xiao H Front Genet. 2022; 13:813268.

PMID: 35450220 PMC: 9016179. DOI: 10.3389/fgene.2022.813268.

References

Long W, Foulds C, Liu J, Ding C, Lonard D, Solis L . ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012; 122(5):1869-80. PMC: 3336992. DOI: 10.1172/JCI61492. View

Liz J, Esteller M . lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015; 1859(1):169-76. DOI: 10.1016/j.bbagrm.2015.06.015. View

Nie W, Ge H, Yang X, Sun X, Huang H, Tao X . LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2015; 371(1):99-106. DOI: 10.1016/j.canlet.2015.11.024. View

Shao Y, Ye M, Li Q, Sun W, Ye G, Zhang X . LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016; 7(25):37812-37824. PMC: 5122351. DOI: 10.18632/oncotarget.9336. View

Ballantyne M, McDonald R, Baker A . lncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol Ther. 2016; 99(5):494-501. PMC: 4881297. DOI: 10.1002/cpt.355. View

Zhang J, Wang J, Zhao F, Liu Q, Jiang K, Yang G . MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010; 411(11-12):846-52. DOI: 10.1016/j.cca.2010.02.074. View

Chen Y, Wang X . miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2019; 48(D1):D127-D131. PMC: 6943051. DOI: 10.1093/nar/gkz757. View

Li S, Mei Z, Hu H, Zhang X . The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 2017; 233(9):6679-6688. DOI: 10.1002/jcp.26325. View

Tan J, Yang L, Liu C, Yan Z . MicroRNA-26a targets MAPK6 to inhibit smooth muscle cell proliferation and vein graft neointimal hyperplasia. Sci Rep. 2017; 7:46602. PMC: 5399463. DOI: 10.1038/srep46602. View

10.

Bian K, Muppani N, Elkhadragy L, Wang W, Zhang C, Chen T . ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. Oncotarget. 2015; 7(6):6665-75. PMC: 4872741. DOI: 10.18632/oncotarget.6682. View

11.

Yang G, Lu X, Yuan L . LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11):1097-109. DOI: 10.1016/j.bbagrm.2014.08.012. View

12.

Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I . Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004; 46(2):171-8. DOI: 10.1016/j.lungcan.2004.03.021. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

14.

Agarwal V, Bell G, Nam J, Bartel D . Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015; 4. PMC: 4532895. DOI: 10.7554/eLife.05005. View

15.

GRAHAM M, Purdy J, Emami B, Harms W, Bosch W, Lockett M . Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45(2):323-9. DOI: 10.1016/s0360-3016(99)00183-2. View

16.

Peters S, Adjei A, Gridelli C, Reck M, Kerr K, Felip E . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii56-64. DOI: 10.1093/annonc/mds226. View

17.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

18.

Pillai R, Artus C, Filipowicz W . Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA. 2004; 10(10):1518-25. PMC: 1370638. DOI: 10.1261/rna.7131604. View

19.

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H . Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-6. DOI: 10.1158/0008-5472.CAN-04-0637. View

20.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View